Lower Blood Pressure After Transcatheter or Surgical Aortic Valve Replacement is Associated with Increased Mortality

Brian R Lindman, Kashish Goel, Javier Bermejo, Joshua Beckman, Jared O'Leary, Colin M Barker, Clayton Kaiser, João L Cavalcante, Sammy Elmariah, Jian Huang, Graeme L Hickey, David H Adams, Jeffrey J Popma, Michael J Reardon, Brian R Lindman, Kashish Goel, Javier Bermejo, Joshua Beckman, Jared O'Leary, Colin M Barker, Clayton Kaiser, João L Cavalcante, Sammy Elmariah, Jian Huang, Graeme L Hickey, David H Adams, Jeffrey J Popma, Michael J Reardon

Abstract

Background Blood pressure (BP) guidelines for patients with aortic stenosis or a history of aortic stenosis treated with aortic valve replacement (AVR) match those in the general population, but this extrapolation may not be warranted. Methods and Results Among patients enrolled in the Medtronic intermediate, high, and extreme risk trials, we included those with a transcatheter AVR (n=1794) or surgical AVR (n=1103) who were alive at 30 days. The associations between early (average of discharge and 30 day post-AVR) systolic BP (SBP) and diastolic BP (DBP) measurements and clinical outcomes between 30 days and 1 year were evaluated. Among 2897 patients, after adjustment, spline curves demonstrated an association between lower SBP (<120 mm Hg, representing 21% of patients) and DBP (<60 mm Hg, representing 30% of patients) and increased all-cause and cardiovascular mortality and repeat hospitalization. These relationships were unchanged when patients with moderate-to-severe aortic regurgitation post-AVR were excluded. After adjustment, compared with DBP 60 to <80 mm Hg, DBP 30 to <60 mm Hg was associated with increased all-cause (adjusted hazard ratio 1.62, 95% CI 1.23-2.14) and cardiovascular mortality (adjusted hazard ratio 2.13, 95% CI 1.52-3.00), but DBP 80 to <100 mm Hg was not. Similarly, after adjustment, compared with SBP 120 to <150 mm Hg, SBP 90 to <120 mm Hg was associated with increased all-cause (adjusted hazard ratio 1.63, 95% CI 1.21-2.21) and cardiovascular mortality (adjusted hazard ratio 1.81, 95% CI 1.25-2.61), but SBP 150 to <180 mm Hg was not. Conclusions Lower BP in the first month after transcatheter AVR or surgical AVR is common and associated with increased mortality and repeat hospitalization. Clarifying optimal BP targets in these patients ought to be a priority and may improve patient outcomes. Clinical Trial Registration Information URL: http://www.clinicaltrials.gov. Unique identifiers: NCT01586910, NCT01240902.

Keywords: aortic valve stenosis; blood pressure; mortality; transcatheter aortic valve implantation.

Figures

Figure 1
Figure 1
Post‐aortic valve replacement diastolic blood pressure and outcomes. Cox proportional hazard models were performed using restricted cubic splines technique. The association between early post‐aortic valve replacement diastolic blood pressure and all‐cause (A), cardiovascular (B), and non‐cardiovascular (C) 30‐day to 1‐year mortality are shown as well as the association with aortic valve‐related hospitalization (D) between 30 days and 1 year. Adjustment was made for: transcatheter aortic valve replacement (vs surgical aortic valve replacement), body mass index, New York Heart Association (III/IV vs I/II), peripheral vascular disease, home oxygen use, prior atrial fibrillation/flutter, liver cirrhosis, immunosuppressive therapy, 5 m gait speed, independent living, early stroke, early life threatening or disabling or major bleed, acute kidney injury, and early myocardial infarction. AVR indicates aortic valve replacement; DBP, diastolic blood pressure.
Figure 2
Figure 2
Post‐aortic valve replacement systolic blood pressure and outcomes. Cox proportional hazard models were performed using restricted cubic splines technique. The association between early post‐aortic valve replacement systolic blood pressure and all‐cause (A), cardiovascular (B), and non‐cardiovascular (C) 30‐day to 1‐year mortality are shown as well as the association with aortic valve‐related hospitalization (D) between 30 days and 1 year. Adjustment was made for the same variables as in Figure 1. AVR indicates aortic valve replacement; SBP, systolic blood pressure.
Figure 3
Figure 3
Post‐aortic valve replacement systolic and diastolic blood pressure and outcomes. Kaplan–Meier curves are shown for all‐cause (A) and cardiovascular (B) mortality between 30 days and 1 year for early post‐aortic valve replacement blood pressure groups defined by systolic blood pressure ≥120 vs <120 mm Hg and diastolic blood pressure ≥60 vs <60 mm Hg. AVR indicates aortic valve replacement; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Figure 4
Figure 4
Discharge and 30‐day diastolic blood pressure and outcomes. Kaplan–Meier curves are shown for all‐cause (A) and cardiovascular (B) mortality between 30 days and 1 year for diastolic blood pressure groups defined by discharge diastolic blood pressure ≥60 vs <60 mm Hg and 30‐day diastolic blood pressure ≥60 vs <60 mm Hg. DBP indicates diastolic blood pressure.

References

    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD; American Collegeof Cardiology, American Heart Association Task Force on Practice G . AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440–2492.
    1. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Munoz DR, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791.
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e484–e594.
    1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta‐analysis. The Lancet. 2016;387:957–967.
    1. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta‐analysis. JAMA Cardiol. 2017;2:775–781.
    1. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood‐pressure control. N Engl J Med. 2015;373:2103–2116.
    1. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel‐Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM, SPRINT Research Group . Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA. 2016;315:2673–2682.
    1. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. Circulation. 2013;128:1281–1283.
    1. Goel SS, Aksoy O, Gupta S, Houghtaling PL, Tuzcu EM, Marwick T, Mihaljevic T, Svensson L, Blackstone EH, Griffin BP, Stewart WJ, Barzilai B, Menon V, Kapadia SR. Renin‐angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study. Ann Intern Med. 2014;161:699–710.
    1. Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, Thourani VH, Carroll JD, Kirtane AJ, Bavaria JE, Cohen DJ, Kiefer TL, Gaca JG, Kapadia SR, Peterson ED, Vemulapalli S. Association of renin‐angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320:2231–2241.
    1. Ochiai T, Saito S, Yamanaka F, Shishido K, Tanaka Y, Yamabe T, Shirai S, Tada N, Araki M, Naganuma T, Watanabe Y, Yamamoto M, Hayashida K. Renin‐angiotensin system blockade therapy after transcatheter aortic valve implantation. Heart. 2018;104:644–651.
    1. Lindman BR, Otto CM, Douglas PS, Hahn RT, Elmariah S, Weissman NJ, Stewart WJ, Ayele GM, Zhang F, Zajarias A, Maniar HS, Jilaihawi H, Blackstone E, Chinnakondepalli KM, Tuzcu EM, Leon MB, Pibarot P. Blood pressure and arterial load after transcatheter aortic valve replacement for aortic stenosis. Circ Cardiovasc Imaging. 2017;10:e006308.
    1. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW, Chenoweth S, Oh JK; CoreValve United States Clinical Investigators . Transcatheter aortic valve replacement using a self‐expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972–1981.
    1. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; U.S. CoreValve Clinical Investigators . Transcatheter aortic‐valve replacement with a self‐expanding prosthesis. N Engl J Med. 2014;370:1790–1798.
    1. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP; SURTAVI Investigators . Surgical or transcatheter aortic‐valve replacement in intermediate‐risk patients. N Engl J Med. 2017;376:1321–1331.
    1. Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer‐Verlag; 2010.
    1. Perlman GY, Loncar S, Pollak A, Gilon D, Alcalai R, Planer D, Lotan C, Danenberg HD. Post‐procedural hypertension following transcatheter aortic valve implantation: incidence and clinical significance. JACC Cardiovasc Interv. 2013;6:472–478.
    1. Yotti R, Bermejo J, Gutierrez‐Ibanes E, Perez del Villar C, Mombiela T, Elizaga J, Benito Y, Gonzalez‐Mansilla A, Barrio A, Rodriguez‐Perez D, Martinez‐Legazpi P, Fernandez‐Aviles F. Systemic vascular load in calcific degenerative aortic valve stenosis: insight from percutaneous valve replacement. J Am Coll Cardiol. 2015;65:423–433.
    1. Messerli FH, Panjrath GS. The J‐curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54:1827–1834.
    1. McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, Coresh J, Selvin E. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713–1722.
    1. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581–584.
    1. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884–893.
    1. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J‐curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489–495.
    1. Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesaniemi YA, Pedersen TR, Willenheimer R, Wachtell K. Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: the SEAS Study. Circulation. 2016;134:455–468.
    1. Peri‐Okonny PA, Patel KK, Jones PG, Breeding T, Gosch KL, Spertus JA, Arnold SV. Low diastolic blood pressure is associated with angina in patients with chronic coronary artery disease. J Am Coll Cardiol. 2018;72:1227–1232.
    1. Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML. The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation. 1988;77:1108–1115.
    1. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK, SPRINT Research Group . Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation. 2018;137:134–143.

Source: PubMed

3
Předplatit